# RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT

> **NCT04776265** · — · UNKNOWN · sponsor: **Grupo Argentino de Tratamiento de la Leucemia Aguda** · enrollment: 100 (estimated)

## Conditions studied

- Hodgkin Lymphoma, Adult
- Relapsed Hodgkin's Disease, Adult
- Refractory Hodgkin Lymphoma

## Interventions

- **OTHER:** Evaluation of therapeutical approach after ASCT

## Key facts

- **NCT ID:** NCT04776265
- **Lead sponsor:** Grupo Argentino de Tratamiento de la Leucemia Aguda
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-01
- **Primary completion:** 2024-03-01
- **Final completion:** 2024-04-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04776265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04776265, "RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04776265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*